,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11110782,2160,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11110783,2160,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11110782,2160,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11110783,2160,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,411,2,1,,11110782,2160,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
5,411,2,1,,11110783,2160,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,444,1,1,,11110782,2160,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
7,444,1,1,,11110783,2160,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
8,445,3,1,,11110782,2160,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
9,445,3,1,,11110783,2160,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
10,446,1,1,,11110782,2160,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
11,446,1,1,,11110783,2160,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
12,447,1,1,,11110782,2160,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
13,447,1,1,,11110783,2160,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
14,448,1,2,,11110782,2160,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
15,448,1,2,,11110783,2160,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11110782,2160,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,450,1,2,,11110783,2160,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
18,451,1,2,,11110782,2160,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
19,451,1,2,,11110783,2160,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
20,526,1,1,,11110782,2160,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
21,526,1,1,,11110783,2160,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
22,530,1,1,,11110782,2160,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
23,530,1,1,,11110783,2160,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
24,584,1,3,,11110782,2160,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
25,584,1,3,,11110783,2160,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
26,585,1,4,,11110782,2160,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
27,585,1,4,,11110783,2160,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
28,587,1,5,,11110782,2160,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
29,587,1,5,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
30,588,1,4,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
31,588,1,4,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
32,589,1,3,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
33,589,1,3,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
34,590,1,3,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
35,590,1,3,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
36,591,1,4,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
37,591,1,4,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
38,592,1,6,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
39,592,1,6,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
40,593,1,4,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
41,593,1,4,,11110783,2160,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
42,594,1,4,,11110782,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
43,594,1,4,,11110783,2160,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
44,595,1,3,,11110782,2160,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
45,595,1,3,,11110783,2160,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
46,596,1,2,,11110782,2160,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
47,596,1,2,,11110783,2160,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
48,597,1,3,,11110782,2160,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
49,597,1,3,,11110783,2160,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
50,603,1,2,,11110782,2160,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
51,603,1,2,,11110783,2160,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
52,605,1,2,,11110782,2160,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
53,605,1,2,,11110783,2160,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
54,607,1,3,,11110782,2160,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
55,607,1,3,,11110783,2160,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
56,662,1,1,,11110782,2160,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
57,662,1,1,,11110783,2160,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
58,875,1,2,,11110782,2160,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
59,875,1,2,,11110783,2160,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
60,879,1,2,,11110782,2160,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
61,879,1,2,,11110782,2160,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
62,880,2,1,,11110783,2160,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
63,880,2,1,,11110783,2160,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,881,2,2,,11110782,2160,Inactive,317373425.0,247.0,25.1189,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
65,881,2,2,,11110783,2160,Inactive,317373425.0,247.0,15.8489,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
66,883,1,3,,11110782,2160,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
67,883,1,3,,11110783,2160,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
68,884,1,2,,11110782,2160,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
69,884,1,2,,11110783,2160,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
70,885,1,2,,11110782,2160,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
71,885,1,2,,11110783,2160,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
72,886,1,2,,11110782,2160,Inconclusive,122921310.0,,7.9433,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
73,886,1,2,,11110782,2160,Inconclusive,122921311.0,,7.9433,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
74,886,1,2,,11110783,2160,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
75,886,1,2,,11110783,2160,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
76,887,1,2,,11110782,2160,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
77,887,1,2,,11110783,2160,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
78,889,1,3,,11110782,2160,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
79,889,1,3,,11110783,2160,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
80,891,1,2,,11110782,2160,Inconclusive,40805836.0,1565.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
81,891,1,2,,11110783,2160,Active,40805836.0,1565.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
82,892,1,2,,11110782,2160,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
83,892,1,2,,11110783,2160,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
84,893,1,2,,11110782,2160,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
85,893,1,2,,11110782,2160,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
86,893,1,2,,11110783,2160,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
87,893,1,2,,11110783,2160,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
88,894,2,1,,11110783,2160,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
89,895,1,2,,11110782,2160,Inconclusive,21620132.0,4790.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
90,899,1,2,,11110782,2160,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
91,899,1,2,,11110783,2160,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
92,900,1,3,,11110782,2160,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
93,900,1,3,,11110783,2160,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
94,901,1,2,,11110782,2160,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
95,901,1,2,,11110783,2160,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
96,902,1,2,,11110782,2160,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
97,902,1,2,,11110783,2160,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
98,912,1,2,,11110782,2160,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
99,912,1,2,,11110783,2160,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
100,914,1,3,,11110782,2160,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
101,914,1,3,,11110783,2160,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
102,915,1,3,,11110782,2160,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
103,915,1,3,,11110783,2160,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
104,917,1,3,,11110782,2160,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
105,918,1,3,,11110782,2160,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
106,923,1,2,,11110782,2160,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
107,923,1,2,,11110783,2160,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
108,924,1,2,,11110782,2160,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
109,924,1,2,,11110783,2160,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
110,925,1,2,,11110782,2160,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
111,925,1,2,,11110783,2160,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
112,926,1,2,,11110782,2160,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
113,926,1,2,,11110783,2160,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
114,927,1,3,,11110782,2160,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
115,927,1,3,,11110783,2160,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
116,928,1,2,,11110782,2160,Inconclusive,21620132.0,4790.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
117,938,1,2,,11110782,2160,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
118,938,1,2,,11110783,2160,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
119,943,1,2,,11110782,2160,Active,18249941.0,25229.0,0.1259,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
120,944,1,2,,11110782,2160,Active,18249941.0,25229.0,0.2239,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
121,945,1,4,,11110782,2160,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
122,954,1,2,,11110782,2160,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
123,957,1,2,,11110782,2160,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
124,958,1,2,,11110782,2160,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
125,959,1,4,,11110782,2160,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
126,992,1,3,,11110782,2160,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
127,995,1,2,,11110782,2160,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
128,995,1,2,,11110783,2160,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
129,997,1,2,,11110782,2160,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
130,998,1,2,,11110782,2160,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
131,1030,2,1,,11110783,2160,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
132,1195,1,2,,48415554,2160,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
133,1332,1,1,,49699308,2160,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
134,1379,1,2,,11110783,2160,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
135,1452,1,1,,11110782,2160,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
136,1452,1,1,,11110783,2160,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
137,1454,1,1,,11110783,2160,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
138,1457,1,1,,11110783,2160,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
139,1458,1,1,,11110783,2160,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
140,1467,1,3,,11110783,2160,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
141,1469,1,1,,11110783,2160,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
142,1471,2,1,,11110782,2160,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
143,1471,2,1,,11110783,2160,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
144,1476,2,1,,11110783,2160,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
145,1477,1,1,,11110783,2160,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
146,1478,2,1,,11110783,2160,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
147,1479,1,2,,11110783,2160,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
148,1487,1,1,,11110783,2160,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
149,1490,2,1,,11110783,2160,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
150,1519,1,3,,11110783,2160,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
151,1766,1,1,,11110783,2160,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
152,1766,1,1,,11110783,2160,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
153,1768,1,1,,11110783,2160,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
154,1768,1,1,,11110783,2160,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
155,1851,1,2,,11110782,2160,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
156,1851,1,2,,11110783,2160,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
157,1851,1,2,1.0,11110782,2160,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
158,1851,1,2,1.0,11110783,2160,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
159,1851,1,2,2.0,11110782,2160,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
160,1851,1,2,2.0,11110783,2160,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
161,1851,1,2,3.0,11110782,2160,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
162,1851,1,2,3.0,11110783,2160,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
163,1851,1,2,4.0,11110782,2160,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
164,1851,1,2,4.0,11110783,2160,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
165,1851,1,2,5.0,11110782,2160,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
166,1851,1,2,5.0,11110783,2160,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
167,1865,1,1,,11110783,2160,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
168,1948,1,1,,11110783,2160,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
169,2062,1,2,,85209738,2160,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
170,2101,1,1,,11110783,2160,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
171,2107,1,1,,11110783,2160,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
172,2112,1,1,,11110783,2160,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
173,2147,1,1,,11110783,2160,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
174,2240,1,1,,85787833,2160,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
175,2241,1,1,,85787833,2160,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
176,2275,1,1,,85787833,2160,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
177,2313,1,1,,85787833,2160,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
178,2316,1,1,,85787833,2160,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
179,2322,1,1,,85787833,2160,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
180,2330,1,1,,85787833,2160,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
181,2451,1,2,,11110783,2160,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
182,2472,1,2,,11110783,2160,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
183,2517,2,1,,11110783,2160,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
184,2528,1,2,,11110783,2160,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
185,2546,1,1,,11110783,2160,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
186,2549,1,1,,11110783,2160,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
187,2551,1,1,,11110783,2160,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
188,2660,1,1,,90340850,2160,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
189,2666,1,1,,90340850,2160,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
190,2667,1,1,,90340850,2160,Inconclusive,4826730.0,2475.0,14.6892,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
191,2668,1,1,,90340850,2160,Inconclusive,4826730.0,2475.0,14.6892,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
192,6418,9,5,,103188772,2160,Active,112808.0,29595.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
193,6418,9,5,,103188772,2160,Active,112812.0,24473.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
194,6418,9,5,,103188772,2160,Active,112815.0,25075.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
195,6418,9,5,,103188772,2160,Active,112817.0,25187.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
196,6418,9,5,,103188772,2160,Active,112820.0,25323.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
197,6418,9,5,,103188772,2160,Active,398968.0,60448.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
198,6418,9,5,,103188772,2160,Active,398970.0,29581.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
199,6418,9,5,,103188772,2160,Active,461440.0,65032.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
200,6418,9,5,,103188772,2160,Active,543729.0,25689.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
201,6418,9,5,,103188772,2160,Active,543730.0,79247.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
202,6418,9,5,,103188772,2160,Active,1168221.0,64354.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
203,6418,9,5,,103188772,2160,Active,1168223.0,79246.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
204,6418,9,5,,103188772,2160,Active,2494928.0,25324.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
205,6418,9,5,,103188772,2160,Active,81868595.0,58963.0,0.044000000000000004,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
206,7783,3,4,,103188772,2160,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
207,8002,5,2,,103188772,2160,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
208,15708,6,1,,103188772,2160,Unspecified,,,,,Plasma clearance for the compound was determined.,Other,10447960.0,
209,19006,4,3,,103188772,2160,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
210,20163,3,3,,103188772,2160,Unspecified,,,,,"The ratio of brain-blood partitioning, (C brain / C blood).",Other,8941388.0,
211,22293,4,4,,103188772,2160,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
212,22345,3,3,,103188772,2160,Unspecified,,,,,Therapeutic plasma levels for the compound was evaluated.,Other,10447960.0,
213,22432,5,2,,103188772,2160,Unspecified,,,,,Volume of distribution in the plasma fluid was determined,Other,10447960.0,
214,22538,3,3,,103188772,2160,Unspecified,,,,,Half life period is estimated,Other,10447960.0,
215,23708,3,3,,103188772,2160,Unspecified,,,,,Partition coefficient (logP),Other,10447960.0,
216,23965,3,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
217,23967,3,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
218,23969,3,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
219,23971,3,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
220,23975,4,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
221,23976,4,3,,103188772,2160,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
222,25866,3,3,,103188772,2160,Unspecified,,,,,Protonation constant of the compound.,Other,10447960.0,
223,26296,4,4,,103188772,2160,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
224,26300,3,5,,103188772,2160,Unspecified,,,,,log P values determined at PH 7.4,Other,10447960.0,
225,26304,4,4,,103188772,2160,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
226,26310,4,4,,103188772,2160,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
227,26362,4,3,,103188772,2160,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
228,26396,3,4,,103188772,2160,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
229,26523,3,4,,103188772,2160,Unspecified,,,,,Partition coefficient (logD) (HPLC),Other,6167716.0,
230,26538,3,3,,103188772,2160,Unspecified,,,,,log K was measured potentiometrically in Brij35 medium,Other,10447960.0,
231,29359,3,3,,103188772,2160,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
232,29811,4,3,,103188772,2160,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
233,34292,8,2,,103188772,2160,Active,,,0.053,Ki,Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase,Confirmatory,10447960.0,
234,34293,8,2,,103188772,2160,Active,,,0.06,Ki,Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase,Confirmatory,10447960.0,
235,36031,7,2,,103188772,2160,Active,,,2e-05,IC50,Compound was tested for its inhibitory activity against Alpha-1 adrenergic receptor,Confirmatory,10447960.0,
236,58617,3,5,,103188772,2160,Unspecified,,,,,Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate..,Other,7452678.0,
237,58619,3,5,,103188772,2160,Unspecified,,,,,Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm.,Other,7452678.0,
238,60003,6,2,,103188772,2160,Unspecified,,,,,Inhibition of the response to phenethylamine was measured,Other,6747994.0,
239,60027,6,2,,103188772,2160,Unspecified,,,,,Potentiation of the response to norepinephrine was measured,Other,6747994.0,
240,78164,8,2,,103188772,2160,Unspecified,,,,,Concentration required to reducing the histamine induced contraction by 50% was measured,Other,7205881.0,
241,87513,8,2,,103188772,2160,Active,,,2e-05,IC50,Compound tested for its inhibitory activity against Histamine H1 receptor,Confirmatory,10447960.0,
242,87880,7,6,,103188772,2160,Active,1346291.0,100729734.0,0.66,IC50,Inhibitory activity against brain adenylate cyclase Histamine H2 receptor,Confirmatory,10447960.0,
243,88009,4,11,,103188772,2160,Active,1346291.0,100729734.0,,,Displacement of [3H](-)-trans-H2-PAT from histamine H2 PAT binding site by competition binding assay.,Other,10447948.0,
244,112337,6,2,,103188772,2160,Unspecified,,,,,Evaluated for antidepressant activity by its ability to inhibit tetrabenazine-induced (TBZ) ptosis in mice,Other,6109027.0,
245,112381,6,2,,103188772,2160,Unspecified,,,,,The effect on 24-hour mortality in mice following oral administration,Other,7265119.0,
246,112383,6,2,,103188772,2160,Unspecified,,,,,The effect on ataxia in mice following oral administration,Other,7265119.0,
247,112385,6,2,,103188772,2160,Unspecified,,,,,The effect on electroshock protection in mice following oral administration,Other,7265119.0,
248,112387,6,2,,103188772,2160,Unspecified,,,,,The effect on excitement was measured in mice following oral administration,Other,7265119.0,
249,112388,6,2,,103188772,2160,Unspecified,,,,,Effect on pupil dilation was measured in mice upon oral administration,Other,7265119.0,
250,112630,6,2,,103188772,2160,Unspecified,,,,,Compound was tested for antidepressant activity by determining the decreased exploratory activity in mice upon oral administration; 2.7-4.6,Other,7265119.0,
251,112649,6,2,,103188772,2160,Unspecified,,,,,Compound was tested for antidepressant activity by determining the reversal of tetrabenazine-induced ptosis upon oral administration; 1.1-1.8,Other,7265119.0,
252,112904,6,2,,103188772,2160,Unspecified,,,,,Evaluated for the prevention of TBZ ptosis by intraperitoneal administration in mice,Other,8558530.0,
253,113162,6,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity by tetrabenazine ptosis prevention in mice after intraperitoneal administration,Other,6602886.0,
254,113163,6,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity by tetrabenazine ptosis prevention in mice after oral administration,Other,6602886.0,
255,114043,6,2,,103188772,2160,Unspecified,,,,,"Muscle relaxant effect was measured as ED50 which is the dose that causes muscle relaxation in 50% of the mice, po",Other,7205881.0,
256,114156,6,2,,103188772,2160,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice,Other,3373495.0,
257,114157,6,2,,103188772,2160,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice,Other,3373495.0,
258,114327,6,2,,103188772,2160,Unspecified,,,,,"Antiphysostigmine effect was measured as ED50,po",Other,7205881.0,
259,114920,3,3,,103188772,2160,Unspecified,,,,,Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 25 mg/kg,Other,2016710.0,
260,116717,6,2,,103188772,2160,Unspecified,,,,,Acute cytotoxicity was evaluated as LD50 in mice (ip),Other,3373495.0,
261,117244,6,2,,103188772,2160,Unspecified,,,,,"Toxicity was measured as LD50,po",Other,7205881.0,
262,118210,3,3,,103188772,2160,Unspecified,,,,,Ability to prevent the reserpine induced hypothermia in mice relative to amitriptyline,Other,7205881.0,
263,125386,6,3,,103188772,2160,Unspecified,,,,,"Effective dose (p.o.) required to inhibit monoamine oxidase, in vivo",Other,6747994.0,
264,125388,6,1,,103188772,2160,Unspecified,,,,,In vitro inhibitory concentration against monoamine oxidase with 5-HT as substrate,Other,6747994.0,
265,127859,6,2,,103188772,2160,Unspecified,,,,,"Compound was evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported, with the percent reversal at 10 mg/kg in parenthesis.",Other,6716399.0,
266,128144,7,2,,103188772,2160,Unspecified,,,,,Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
267,128147,7,2,,103188772,2160,Unspecified,,,,,Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
268,129182,6,2,,103188772,2160,Unspecified,,,,,Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after i.p. administration.,Other,6970818.0,
269,129284,7,2,,103188772,2160,Unspecified,,,,,Antidepressant activity was measured by the inhibition of tetrabenazine ptosis in mice after po administration.,Other,6970818.0,
270,130126,6,2,,103188772,2160,Unspecified,,,,,Compound was evaluated for maximal electroshock antagonism (MES) against mice (values in parentheses indicates 95% confidence limits),Other,6716399.0,
271,130694,6,2,,103188772,2160,Unspecified,,,,,In vivo for the inhibition of potentiation of yohimbine -induced toxicity in mouse,Other,7200144.0,
272,130712,6,2,,103188772,2160,Unspecified,,,,,In vivo inhibition of uptake of nor epinephrine in mouse heart,Other,4009590.0,
273,131006,6,2,,103188772,2160,Unspecified,,,,,Compound was tested for physostigmine lethality in mouse.,Other,7200144.0,
274,131167,6,2,,103188772,2160,Unspecified,,,,,Compound was tested in vivo for antagonism of oxotremorine induced -tremors in mouse.,Other,7200144.0,
275,131168,6,2,,103188772,2160,Unspecified,,,,,Compound was tested in vivo for antagonism of oxotremorine induced salivation in mouse.,Other,7200144.0,
276,131173,6,2,,103188772,2160,Unspecified,,,,,Compound was tested in vivo for potential antidepressant activity which was assessed by its prevention of tetrabenazine-induced ptosis in mice,Other,7200144.0,
277,131702,6,2,,103188772,2160,Unspecified,,,,,Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in mouse,Other,6747994.0,
278,131718,6,2,,103188772,2160,Unspecified,,,,,Effective dose against oxotremorine induced lacrimation,Other,6747994.0,
279,131719,6,2,,103188772,2160,Unspecified,,,,,Effective dose against oxotremorine induced tremor,Other,6747994.0,
280,131997,3,3,,103188772,2160,Unspecified,,,,,Evaluated for antagonism of reserpine induced hypothermia,Other,6716399.0,
281,132407,6,2,,103188772,2160,Unspecified,,,,,Inhibition of tetrabenazine-induced ptosis in mice following i.p. administration.,Other,7241520.0,
282,132413,6,2,,103188772,2160,Unspecified,,,,,Inhibition of tetrabenazine-induced ptosis (TBZ) in mice by peroral administration,Other,7069712.0,
283,132432,7,2,,103188772,2160,Unspecified,,,,,Ex vivo inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain. (i.p.),Other,2966246.0,
284,132433,7,2,,103188772,2160,Unspecified,,,,,Ex vivo inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain. (i.p.),Other,2966246.0,
285,132583,8,1,,103188772,2160,Active,,,5.4,ED50,In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.,Confirmatory,4009610.0,
286,132584,8,1,,103188772,2160,Active,,,2.9,ED50,In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.,Confirmatory,4009610.0,
287,132671,6,2,,103188772,2160,Active,,,2.9,IC50,In vitro inhibition of the accumulation of (-)-[3H]-5-HT in slices from the middle part of the mouse brain.,Confirmatory,2966246.0,
288,132672,6,2,,103188772,2160,Active,,,5.4,IC50,In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in slices from the middle part of the mouse brain.,Confirmatory,2966246.0,
289,132759,6,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity measured by yohimbine toxicity potentiation in mouse after intraperitoneal administration,Other,6602886.0,
290,132760,7,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity assessed by prevention of tetrabenazine-induced ptosis in mice following i.p. administration.,Other,7200144.0,
291,134421,6,2,,103188772,2160,Unspecified,,,,,Compound was evaluated for lethal dose in mouse in groups of ten (values in parentheses indicates 95% confidence limits),Other,6716399.0,
292,134634,3,3,,103188772,2160,Unspecified,,,,,Antagonism of reserpine-induced hypothermia in mice,Other,4009590.0,
293,134949,3,3,,103188772,2160,Active,,,,,Mouse behavior activity was determined; ST = Stimulant(Weak),Other,6716399.0,
294,137278,3,3,,103188772,2160,Unspecified,,,,,Reserpine hypothermia antagonism in mouse administered perorally with 5 mg/kg of reserpine 2 hour prior to test compound administration,Other,6716399.0,
295,140140,6,2,,103188772,2160,Unspecified,,,,,Inhibition of radioactive NE [3H]norepinephrine uptake into mouse heart,Other,6716399.0,
296,141676,9,1,,103188772,2160,Active,,,0.3,IC50,Inhibition of radioligand [3H]QNB binding to muscarinic acetylcholine receptor in the rat forebrain in the presence of zinc,Confirmatory,8558530.0,
297,142620,8,3,,103188772,2160,Active,,,3.0,IC50,Compound was tested in vitro for its ability to displace [3H]quinuclidine benzylate (QNB) from Muscarinic acetylcholine receptor on rat whole brain membranes.,Confirmatory,7200144.0,
298,145715,9,1,,103188772,2160,Active,,,2.5,IC50,Inhibition of the NE [3H]norepinephrine uptake by rat brain slices In vitro,Confirmatory,6716399.0,
299,147591,8,2,,103188772,2160,Active,,,0.040999999999999995,IC50,Compound was tested for its inhibitory activity against Noradrenaline receptor,Confirmatory,10447960.0,
300,161281,10,5,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
301,176977,6,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity against muricide in rat after intraperitoneal administration,Other,6602886.0,
302,176979,6,2,,103188772,2160,Unspecified,,,,,In vivo antidepressant activity measured by potentiation of head twitching induced by 5-HTP in pargyline-pretreated rats after intraperitoneal administration,Other,6602886.0,
303,177672,6,2,,103188772,2160,Unspecified,,,,,Effective concentration required for potentiation of L-5-hydroxytryptophan-induced seizures (head-twitching) in rats (administered intraperitoneally),Other,7241520.0,
304,177981,6,2,,103188772,2160,Unspecified,,,,,Compound was screened in vivo for antidepressant activity by 5 HTP potentiation method in rat.,Other,7200144.0,
305,178370,6,2,,103188772,2160,Unspecified,,,,,Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in rat,Other,6747994.0,
306,178457,6,2,,103188772,2160,Unspecified,,,,,Antidepressant activity was measured by the potentiation of head twitching induced by 5-hydroxy-tryptophan in pargyline-pretreated rats after ip administration,Other,6970818.0,
307,179243,6,3,,103188772,2160,Active,,,14.0,IC50,In vitro inhibition against neuronal uptake of dopamine in striatum.,Confirmatory,7200144.0,
308,179246,6,3,,103188772,2160,Active,,,4.7,IC50,In vitro inhibition against neuronal uptake of norepinephrine in whole brain,Confirmatory,7200144.0,
309,179247,6,3,,103188772,2160,Active,,,2.0,IC50,In vitro inhibition against neuronal uptake of serotonin in whole brain.,Confirmatory,7200144.0,
310,179739,6,3,,103188772,2160,Active,,,14.0,IC50,In vitro inhibition of neuronal uptake against dopamine in rat striatum,Confirmatory,6602886.0,
311,179741,6,2,,103188772,2160,Active,,,4.7,IC50,In vitro inhibition of neuronal uptake against norepinephrine in rat whole brain,Confirmatory,6602886.0,
312,179742,6,2,,103188772,2160,Active,,,2.0,IC50,In vitro inhibition of neuronal uptake against serotonin in rat whole brain,Confirmatory,6602886.0,
313,179752,6,3,,103188772,2160,Active,,,0.32,IC50,In vitro inhibition of the accumulation of (-)-[3H]-5-HT in synaptosomes from the rat brain cortex,Confirmatory,2966246.0,
314,179753,6,3,,103188772,2160,Active,,,0.061,IC50,In vitro inhibition of the accumulation of (-)-[3H]Norepinephrine in synaptosomes from the rat brain cortex,Confirmatory,2966246.0,
315,180129,6,2,,103188772,2160,Active,,,12.0,IC50,Inhibition of uptake of 5-HT in rat brain slices,Confirmatory,4009590.0,
316,180130,6,2,,103188772,2160,Active,,,12.0,IC50,Inhibition of uptake of Dopamine in rat brain slices,Confirmatory,4009590.0,
317,180131,6,2,,103188772,2160,Active,,,2.5,IC50,Inhibition of uptake of nor epinephrine in rat brain slices,Confirmatory,4009590.0,
318,181621,3,3,,103188772,2160,Unspecified,,,,,Antimuricide effect was observed in the olfactory bulb removed rats; antimuricide effect at 30 mg/kg; + = 31 - 50%,Other,7205881.0,
319,186207,3,3,,103188772,2160,Unspecified,,,,,Log (1/ED50*10e-3) was measured as histamine releasing activity in rat mast cells. c,Other,6167716.0,
320,189474,3,3,,103188772,2160,Unspecified,,,,,Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.,Other,6167716.0,
321,204368,9,2,,103188772,2160,Active,,,8.5,IC50,In vitro inhibition of [14C]5-HT transporter uptake by rat brain slices,Confirmatory,6716399.0,
322,205267,9,2,,103188772,2160,Active,,,10.0,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
323,205268,4,7,,103188772,2160,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
324,211846,6,3,,103188772,2160,Unspecified,,,,,Acute toxicity (p.o.) after 24 hr was determined in mouse,Other,6747994.0,
325,214939,7,3,,103188772,2160,Unspecified,,,60.0,Km,Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4),Confirmatory,12699380.0,
326,222148,5,6,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1,Confirmatory,12190308.0,
327,227283,3,3,,103188772,2160,Unspecified,,,,,Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-1 (SB-1) at 10 mg/kg dose,Other,11462981.0,
328,227286,3,3,,103188772,2160,Unspecified,,,,,Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-2 (SB-2) at 10 mg/kg dose,Other,11462981.0,
329,227290,3,3,,103188772,2160,Unspecified,,,,,Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-3 (SB-3) at 10 mg/kg dose,Other,11462981.0,
330,227718,7,1,,103188772,2160,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
331,232041,3,3,,103188772,2160,Unspecified,,,,,Selectivity expressed as ratio between NE and 5-HT uptake inhibition in mouse brain slices,Other,2966246.0,
332,232042,3,5,,103188772,2160,Unspecified,,,,,Selectivity expressed as ratio between NE and 5-HT uptake inhibition in rat synaptosomes,Other,2966246.0,
333,243151,7,2,,103188772,2160,Active,,,10.0,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
334,243188,6,6,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state,Confirmatory,15745831.0,
335,243422,3,10,,103188772,2160,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
336,311932,3,10,,103188772,2160,Unspecified,224471897.0,6609.0,,,Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM,Other,18027916.0,
337,311934,3,3,,103188772,2160,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
338,311935,3,4,,103188772,2160,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
339,343685,3,3,,103188772,2160,Unspecified,,,,,Ratio of drug level in brain to blood in Wistar rat,Other,18558667.0,
340,386623,4,8,,103188772,2160,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
341,386625,9,5,,103188772,2160,Active,313104181.0,6580.0,16.9,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
342,392463,8,5,,103188772,2160,Unspecified,17367264.0,11255.0,1.0,Ki,Displacement of [125I]iodoproxyfan from human histamine H3 receptor expressed in CHO/HEK293 cells,Confirmatory,19091563.0,
343,392464,8,5,,103188772,2160,Active,547645.0,3269.0,0.00112,Ki,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Confirmatory,19091563.0,
344,392465,8,5,,103188772,2160,Active,118228.0,1812.0,0.08900000000000001,Ki,Displacement of [3H]SCH23390 from human dopamine D1 receptor expressed in HEK cells,Confirmatory,19091563.0,
345,392466,8,5,,103188772,2160,Active,118214.0,1816.0,0.17,Ki,Displacement of [3H]SCH23390 from human dopamine D5 receptor expressed in HEK cells,Confirmatory,19091563.0,
346,392467,8,5,,103188772,2160,Active,118206.0,1813.0,0.196,Ki,Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells,Confirmatory,19091563.0,
347,392468,8,5,,103188772,2160,Active,1169206.0,1814.0,0.20600000000000002,Ki,Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells,Confirmatory,19091563.0,
348,404304,3,10,,103188772,2160,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
349,408340,8,5,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
350,420668,8,5,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human ERG in MCF7 cells,Confirmatory,19110341.0,
351,420669,3,4,,103188772,2160,Unspecified,,,,,"Lipophilicity, log D at pH 7.0",Other,19110341.0,
352,425652,7,2,,103188772,2160,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
353,425653,7,2,,103188772,2160,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
354,434959,1,1,,85787833,2160,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
355,444050,7,1,,103188772,2160,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
356,444051,6,2,,103188772,2160,Unspecified,,,,,Total clearance in human,Other,20070106.0,
357,444052,6,2,,103188772,2160,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
358,444053,6,2,,103188772,2160,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
359,444054,6,1,,103188772,2160,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
360,444055,3,3,,103188772,2160,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
361,444056,3,3,,103188772,2160,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
362,444057,3,3,,103188772,2160,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
363,444058,6,2,,103188772,2160,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
364,463106,1,2,,90340850,2160,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
365,467611,3,6,,103188772,2160,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
366,467612,3,6,,103188772,2160,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
367,467613,5,3,,103188772,2160,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
368,485281,1,1,,11110783,2160,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
369,485290,1,1,,11110783,2160,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
370,485295,1,2,,90340850,2160,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
371,485297,1,1,,90340850,2160,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
372,485298,1,1,,90340850,2160,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
373,485313,1,2,,90340850,2160,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
374,485342,1,2,,90340850,2160,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
375,485345,1,2,,90340850,2160,Inconclusive,,,16.3601,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
376,485366,1,2,,90340850,2160,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
377,485368,1,2,,90340850,2160,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
378,488772,1,1,,90340850,2160,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
379,488773,1,2,,90340850,2160,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
380,488816,1,1,,90340850,2160,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
381,488837,1,1,,90340850,2160,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
382,488949,1,2,,90340850,2160,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
383,488953,1,1,,90340850,2160,Inconclusive,187960037.0,10951.0,25.1189,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
384,488978,1,1,,90340850,2160,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
385,488981,1,1,,90340850,2160,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
386,488982,1,1,,90340850,2160,Inactive,4503383.0,1812.0,0.2593,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
387,488983,1,1,,90340850,2160,Active,4503383.0,1812.0,1.122,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
388,493106,1,1,,90340850,2160,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
389,493107,1,1,,90340850,2160,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
390,493153,1,1,,90340850,2160,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
391,493153,1,1,,90340850,2160,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
392,493164,1,2,,90340850,2160,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
393,493164,1,2,,90340850,2160,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
394,493164,1,2,,90340850,2160,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
395,496817,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
396,496818,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
397,496819,4,2,,103188772,2160,Unspecified,,,558.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
398,496820,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
399,496821,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
400,496823,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
401,496824,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
402,496825,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
403,496826,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
404,496827,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
405,496828,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
406,496829,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
407,496830,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
408,496831,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
409,496832,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
410,497005,4,2,,103188772,2160,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
411,504327,1,1,,11110783,2160,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
412,504327,1,1,,90340850,2160,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
413,504332,1,1,,11110783,2160,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
414,504332,1,1,,90340850,2160,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
415,504536,1,1,,90340850,2160,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
416,504547,1,1,,90340850,2160,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
417,504548,1,2,,90340850,2160,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
418,504810,1,2,,90340850,2160,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
419,504812,1,2,,90340850,2160,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
420,504836,1,2,,90340850,2160,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
421,504845,1,1,,90340850,2160,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
422,504847,1,1,,11110783,2160,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
423,504847,1,1,,90340850,2160,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
424,504865,1,1,,11110783,2160,Inconclusive,118600387.0,7398.0,39.8107,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
425,504865,1,1,,90340850,2160,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
426,515780,5,1,,103188772,2160,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
427,532573,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method,Other,18694955.0,
428,532574,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrB::aph mutant by broth dilution method,Other,18694955.0,
429,532575,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrD::aph mutant by broth dilution method,Other,18694955.0,
430,532576,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrF::aph mutant by broth dilution method,Other,18694955.0,
431,532577,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing tolC::aph mutant by broth dilution method,Other,18694955.0,
432,532578,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing marA::aph mutant by broth dilution method,Other,18694955.0,
433,532579,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing soxS::aph mutant by broth dilution method,Other,18694955.0,
434,532580,5,2,,103188772,2160,Unspecified,,,,,Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method,Other,18694955.0,
435,540209,4,3,,103188772,2160,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
436,540210,4,3,,103188772,2160,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
437,540211,2,5,,103188772,2160,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
438,540212,4,3,,103188772,2160,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
439,540213,4,3,,103188772,2160,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
440,540234,2,5,,103188772,2160,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
441,540237,2,3,,103188772,2160,Active,,,,,Phospholipidosis-positive literature compound observed in rat,Other,17428028.0,
442,540256,1,2,,90340850,2160,Active,,,9.1962,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
443,540276,1,2,,11110782,2160,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
444,540276,1,2,,11110783,2160,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
445,540276,1,2,,50100171,2160,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
446,540276,1,2,,50104298,2160,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
447,540276,1,2,,90340850,2160,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
448,547621,4,3,,103188772,2160,Active,,,23.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
449,547622,4,2,,103188772,2160,Active,,,12.0,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
450,547804,1,3,,103188772,2160,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
451,576612,7,5,,103188772,2160,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
452,588208,2,3,,103188772,2160,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
453,588211,2,3,,103188772,2160,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
454,588212,2,3,,103188772,2160,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
455,588213,2,3,,103188772,2160,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
456,588214,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
457,588215,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
458,588216,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
459,588217,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
460,588218,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
461,588219,2,3,,103188772,2160,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
462,588220,2,3,,103188772,2160,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
463,588349,1,1,,90340850,2160,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
464,588378,1,1,,90340850,2160,Inconclusive,171543895.0,6311.0,12.5893,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
465,588453,1,1,,90340850,2160,Inconclusive,8659577.0,58819.0,28.1838,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
466,588456,1,1,,90340850,2160,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
467,588579,1,1,,11110783,2160,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
468,588579,1,1,,90340850,2160,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
469,588795,1,1,,90340850,2160,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
470,589038,1,10,,103188772,2160,Unspecified,84028191.0,1565.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
471,589070,1,10,,103188772,2160,Unspecified,136731.0,54657.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A4,Other,,
472,602332,1,1,,11110783,2160,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
473,602332,1,1,,90340850,2160,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
474,602332,1,1,,124879281,2160,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
475,604020,1,4,,103188772,2160,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
476,604021,3,1,,103188772,2160,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
477,604022,1,4,,103188772,2160,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
478,604023,1,3,,103188772,2160,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
479,604024,1,3,,103188772,2160,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
480,604025,1,4,,103188772,2160,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
481,604026,1,4,,103188772,2160,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
482,624030,1,2,,124879281,2160,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
483,624146,1,1,,90340850,2160,Inconclusive,71051501.0,2744.0,2.5119,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
484,624147,1,1,,90340850,2160,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
485,624148,1,2,,90340850,2160,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
486,624149,1,1,,90340850,2160,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
487,624156,1,1,,85787833,2160,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
488,624170,1,1,,124879281,2160,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
489,624172,1,1,,124879281,2160,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
490,624173,1,3,,124879281,2160,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
491,624180,1,1,,135649939,2160,Active,12621102.0,65032.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT7,Other,8394362.0,
492,624183,1,1,,135649939,2160,Active,113865998.0,15566.0,,,Antagonists at Mouse 5-Hydroxytryptamine receptor 5-HT7,Other,8394987.0,
493,624190,1,1,,135649939,2160,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,7680751.0,
494,624190,1,1,,135649939,2160,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9225298.0,
495,624190,1,1,,135649939,2160,Active,13242259.0,64354.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT6,Other,9730917.0,
496,624192,1,1,,135649939,2160,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,8522988.0,
497,624192,1,1,,135649939,2160,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,9284367.0,
498,624192,1,1,,135649939,2160,Active,4504545.0,3362.0,,,Antagonists at Human 5-Hydroxytryptamine receptor 5-HT6,Other,9730917.0,
499,624208,1,1,,135649939,2160,Active,17298688.0,25187.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2C,Other,8876023.0,
500,624222,1,1,,135649939,2160,Active,8393583.0,29595.0,,,Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A,Other,8876023.0,
501,624455,1,1,,90340850,2160,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
502,624606,1,9,,103188772,2160,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
503,624607,1,9,,103188772,2160,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
504,624608,3,2,,103188772,2160,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
505,624609,1,9,,103188772,2160,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
506,624610,1,9,,103188772,2160,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
507,624612,1,9,,103188772,2160,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
508,624613,1,9,,103188772,2160,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
509,624632,3,7,,103188772,2160,Unspecified,549152.0,54659.0,267.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A3,Confirmatory,15781124.0,
510,624633,3,7,,103188772,2160,Unspecified,136731.0,54657.0,100.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A4,Confirmatory,15781124.0,
511,624654,3,4,,103188772,2160,Unspecified,,,130.0,Ki,Inhibition of codeine glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
512,624658,3,4,,103188772,2160,Unspecified,,,160.0,Ki,Inhibition of morphine (3-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
513,624659,3,4,,103188772,2160,Unspecified,,,80.0,Ki,Inhibition of morphine (6-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
514,625144,5,5,,103188772,2160,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
515,625145,4,7,,103188772,2160,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
516,625146,5,5,,103188772,2160,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
517,625147,4,7,,103188772,2160,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
518,625148,4,7,,103188772,2160,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
519,625149,4,7,,103188772,2160,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
520,625150,5,5,,103188772,2160,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
521,625151,4,7,,103188772,2160,Active,113118.0,1128.0,0.011000000000000001,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
522,625152,4,7,,103188772,2160,Active,113122.0,1129.0,0.081,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
523,625153,4,7,,103188772,2160,Active,113125.0,1131.0,0.026000000000000002,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
524,625154,4,7,,103188772,2160,Active,23503039.0,1132.0,0.0053,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
525,625155,4,7,,103188772,2160,Active,543761.0,1133.0,0.008020000000000001,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
526,625156,1,9,,103188772,2160,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
527,625157,6,2,,103188772,2160,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
528,625158,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
529,625159,5,5,,103188772,2160,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
530,625160,1,9,,103188772,2160,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
531,625161,4,7,,103188772,2160,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
532,625162,4,7,,103188772,2160,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
533,625163,4,7,,103188772,2160,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
534,625164,1,6,,103188772,2160,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
535,625165,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
536,625166,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
537,625167,5,5,,103188772,2160,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
538,625168,4,7,,103188772,2160,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
539,625169,1,6,,103188772,2160,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
540,625170,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
541,625171,4,7,,103188772,2160,Active,7531135.0,3757.0,17.5894,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
542,625172,4,7,,103188772,2160,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
543,625173,5,5,,103188772,2160,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
544,625174,5,5,,103188772,2160,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
545,625175,5,5,,103188772,2160,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
546,625176,1,9,,103188772,2160,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
547,625177,5,5,,103188772,2160,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
548,625178,5,5,,103188772,2160,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
549,625179,1,9,,103188772,2160,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
550,625180,5,5,,103188772,2160,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
551,625181,5,5,,103188772,2160,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
552,625182,5,5,,103188772,2160,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
553,625183,5,5,,103188772,2160,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
554,625184,5,5,,103188772,2160,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
555,625185,5,5,,103188772,2160,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
556,625186,5,5,,103188772,2160,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
557,625187,5,5,,103188772,2160,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
558,625188,1,9,,103188772,2160,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
559,625189,1,7,,103188772,2160,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
560,625190,4,5,,103188772,2160,Active,,,1.996,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
561,625191,4,7,,103188772,2160,Active,112815.0,25075.0,3.73,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
562,625192,4,7,,103188772,2160,Active,543727.0,3356.0,0.015,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
563,625193,5,5,,103188772,2160,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
564,625194,4,7,,103188772,2160,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
565,625195,4,7,,103188772,2160,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
566,625196,5,6,,103188772,2160,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
567,625197,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
568,625198,4,7,,103188772,2160,Active,1168247.0,29412.0,0.013999999999999999,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
569,625199,4,7,,103188772,2160,Active,543734.0,24173.0,0.076,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
570,625200,4,7,,103188772,2160,Active,1168243.0,146.0,0.105,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
571,625201,4,7,,103188772,2160,Active,1351829.0,150.0,0.35100000000000003,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
572,625202,4,7,,103188772,2160,Active,613504690.0,151.0,0.00808,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
573,625203,4,7,,103188772,2160,Active,20141211.0,152.0,0.059000000000000004,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
574,625204,4,7,,103188772,2160,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
575,625205,4,7,,103188772,2160,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
576,625206,4,7,,103188772,2160,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
577,625207,4,7,,103188772,2160,Active,128616.0,6530.0,0.023,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
578,625208,5,5,,103188772,2160,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
579,625209,4,7,,103188772,2160,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
580,625210,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
581,625211,1,6,,103188772,2160,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
582,625212,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
583,625213,4,7,,103188772,2160,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
584,625214,1,9,,103188772,2160,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
585,625215,3,4,,103188772,2160,Active,,,1.992,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
586,625216,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
587,625217,4,7,,103188772,2160,Active,1168220.0,3357.0,0.07,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
588,625218,4,7,,103188772,2160,Active,112816.0,3358.0,0.00605,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
589,625219,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
590,625220,4,7,,103188772,2160,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
591,625221,4,7,,103188772,2160,Active,1703010.0,3362.0,0.14,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
592,625222,4,7,,103188772,2160,Active,400630.0,6532.0,0.0016600000000000002,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
593,625223,4,7,,103188772,2160,Active,74752153.0,10280.0,1.031,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
594,625224,3,4,,103188772,2160,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
595,625225,3,4,,103188772,2160,Active,,,2.2880000000000003,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
596,625226,4,7,,103188772,2160,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
597,625227,4,7,,103188772,2160,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
598,625228,4,7,,103188772,2160,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
599,625229,5,5,,103188772,2160,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
600,625230,1,6,,103188772,2160,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
601,625231,4,7,,103188772,2160,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
602,625232,1,9,,103188772,2160,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
603,625233,4,7,,103188772,2160,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
604,625234,3,4,,103188772,2160,Active,,,0.84,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
605,625235,4,7,,103188772,2160,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
606,625236,5,5,,103188772,2160,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
607,625237,4,7,,103188772,2160,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
608,625238,4,7,,103188772,2160,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
609,625239,4,7,,103188772,2160,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
610,625240,1,9,,103188772,2160,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
611,625241,4,7,,103188772,2160,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
612,625242,4,7,,103188772,2160,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
613,625243,5,5,,103188772,2160,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
614,625244,5,5,,103188772,2160,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
615,625245,5,5,,103188772,2160,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
616,625246,1,9,,103188772,2160,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
617,625247,5,5,,103188772,2160,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
618,625248,5,5,,103188772,2160,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
619,625249,5,5,,103188772,2160,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
620,625250,5,5,,103188772,2160,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
621,625251,5,5,,103188772,2160,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
622,625252,4,7,,103188772,2160,Active,118228.0,1812.0,0.355,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
623,625253,4,7,,103188772,2160,Active,118206.0,1813.0,1.0090000000000001,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
624,625254,4,7,,103188772,2160,Active,1169206.0,1814.0,0.182,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
625,625255,4,7,,103188772,2160,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
626,625256,4,7,,103188772,2160,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
627,625257,4,7,,103188772,2160,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
628,625258,4,7,,103188772,2160,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
629,625259,4,7,,103188772,2160,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
630,625260,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
631,625261,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
632,625262,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
633,625263,4,7,,103188772,2160,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
634,625264,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
635,625265,1,6,,103188772,2160,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
636,625266,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
637,625267,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
638,625268,4,2,,103188772,2160,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
639,625268,4,2,,103188772,2160,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
640,625268,4,2,,103188772,2160,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
641,625268,4,2,,103188772,2160,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
642,625269,4,7,,103188772,2160,Active,547645.0,3269.0,0.0047799999999999995,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
643,625270,4,7,,103188772,2160,Active,123120.0,3274.0,0.73,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
644,625271,5,5,,103188772,2160,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
645,625272,3,4,,103188772,2160,Active,,,1.685,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
646,625273,4,6,,103188772,2160,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
647,625274,1,6,,103188772,2160,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
648,625275,3,4,,103188772,2160,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
649,625279,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
650,625280,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
651,625281,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
652,625282,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
653,625283,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
654,625284,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
655,625285,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
656,625286,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
657,625287,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
658,625288,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
659,625289,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
660,625290,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
661,625291,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
662,625292,1,3,,103188772,2160,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
663,651635,1,3,,11110783,2160,Inconclusive,171543895.0,6311.0,6.3096,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
664,651635,1,3,,90340850,2160,Inconclusive,171543895.0,6311.0,25.1189,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
665,651741,1,1,,124879280,2160,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
666,652106,1,1,,90340850,2160,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
667,678712,1,8,,103188772,2160,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
668,678713,1,8,,103188772,2160,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
669,678714,1,8,,103188772,2160,Unspecified,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
670,678715,1,8,,103188772,2160,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
671,678716,1,8,,103188772,2160,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
672,678717,1,8,,103188772,2160,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
673,678718,1,5,,103188772,2160,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
674,678722,1,5,,103188772,2160,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
675,679776,1,8,,103188772,2160,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Amitriptyline: 100 uM) in MDR1-expressing MDCKII cells",Other,12438524.0,
676,680105,1,8,,103188772,2160,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,10700657.0,
677,681116,1,8,,103188772,2160,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,12438524.0,
678,681118,1,8,,103188772,2160,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
679,686977,2,1,,49699308,2160,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
680,699539,1,7,,103188772,2160,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
681,699540,1,7,,103188772,2160,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
682,699541,1,7,,103188772,2160,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
683,699984,1,2,,103188772,2160,Unspecified,,,,,Selectivity ratio of IC50 for human NaV1.7 F1737A mutant at -65 mV holding potential to IC50 for recombinant human NaV1.7 alpha subunit at -65 mV holding potential,Other,22770500.0,
684,700008,1,2,,103188772,2160,Unspecified,,,,,Selectivity ratio of IC50 for human NaV1.5 alpha subunit at -90 mV holding potential to IC50 for recombinant human NaV1.7 alpha subunit at -65 mV holding potential,Other,22770500.0,
685,700020,4,5,,103188772,2160,Active,25014053.0,6326.0,3.1,IC50,Inhibition of human NaV1.2 alpha subunit expressed in CHOK1 cells at -65 mV holding potential by patch clamp electrophysiological assay,Confirmatory,22770500.0,
686,700021,2,2,,103188772,2160,Active,,,12.0,IC50,Inhibition of human NaV1.7 F1737A mutant expressed in HEK293 cells at -65 mV holding potential by patch clamp electrophysiological assay,Confirmatory,22770500.0,
687,700026,4,5,,103188772,2160,Active,215273881.0,6331.0,1.6,IC50,Inhibition of human NaV1.5 alpha subunit expressed in CHOK1 cells at -90 mV holding potential by patch clamp electrophysiological assay,Confirmatory,22770500.0,
688,700027,4,5,,103188772,2160,Active,327478559.0,6335.0,7.0,IC50,Inhibition of recombinant human NaV1.7 alpha subunit expressed in HEK293 cells at -90 mV holding potential by patch clamp electrophysiological assay,Confirmatory,22770500.0,
689,700028,4,5,,103188772,2160,Active,327478559.0,6335.0,1.0,IC50,Inhibition of recombinant human NaV1.7 alpha subunit expressed in HEK293 cells at -65 mV holding potential by patch clamp electrophysiological assay,Confirmatory,22770500.0,
690,720532,1,1,,11110783,2160,Active,420597.0,,7.9433,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
691,720533,1,1,,11110783,2160,Inconclusive,,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
692,720538,1,2,,90340850,2160,Inconclusive,220983390.0,410.0,3.0131,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
693,720559,1,2,,90340850,2160,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
694,720572,1,2,,90340850,2160,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
695,720573,1,2,,90340850,2160,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
696,720636,1,1,,124879280,2160,Inconclusive,20149576.0,4780.0,1.9331,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
697,743205,1,1,,90340850,2160,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
698,743205,1,1,,90340850,2160,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
699,743206,1,1,,90340850,2160,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
700,743206,1,1,,90340850,2160,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
701,743207,1,1,,90340850,2160,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
702,743207,1,1,,90340850,2160,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
703,743244,1,1,,90340850,2160,Active,,,1.2589,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
704,752491,2,3,,103188772,2160,Active,400630.0,6532.0,,IC50,Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,Confirmatory,23602445.0,
705,752492,2,3,,103188772,2160,Active,128616.0,6530.0,,IC50,Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,Confirmatory,23602445.0,
706,752493,2,3,,103188772,2160,Active,266667.0,6531.0,,IC50,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay,Confirmatory,23602445.0,
707,781326,1,2,,103188772,2160,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
708,781328,1,2,,103188772,2160,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
709,781329,1,2,,103188772,2160,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
710,781330,1,2,,103188772,2160,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
711,859008,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/8,Other,,
712,859009,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/8,Other,,
713,859010,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/8,Other,,
714,859011,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/8,Other,,
715,859012,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/8,Other,,
716,859013,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/9,Other,,
717,859014,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/9,Other,,
718,859015,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/9,Other,,
719,859016,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/9,Other,,
720,859017,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/9,Other,,
721,859018,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/9,Other,,
722,859019,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/9,Other,,
723,859020,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/9,Other,,
724,859021,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/9,Other,,
725,859022,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/9,Other,,
726,859023,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/9,Other,,
727,859024,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/9,Other,,
728,859025,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/9,Other,,
729,859026,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/9,Other,,
730,859027,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/9,Other,,
731,859028,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/9,Other,,
732,859029,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/9,Other,,
733,859030,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/9,Other,,
734,859031,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/9,Other,,
735,859032,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/9,Other,,
736,859033,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/9,Other,,
737,859034,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/10,Other,,
738,859035,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/10,Other,,
739,859036,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/10,Other,,
740,859037,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/10,Other,,
741,859038,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/10,Other,,
742,859039,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/10,Other,,
743,859040,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/10,Other,,
744,859041,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/10,Other,,
745,859042,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/10,Other,,
746,859043,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/10,Other,,
747,859044,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/10,Other,,
748,859045,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/10,Other,,
749,859046,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/10,Other,,
750,859047,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/10,Other,,
751,894948,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/11,Other,,
752,894949,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/11,Other,,
753,894950,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/11,Other,,
754,894951,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/11,Other,,
755,894952,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/11,Other,,
756,894953,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/11,Other,,
757,894954,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/11,Other,,
758,894955,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/11,Other,,
759,894956,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/11,Other,,
760,894957,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/11,Other,,
761,894958,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/11,Other,,
762,894959,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/11,Other,,
763,894960,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/11,Other,,
764,894961,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/11,Other,,
765,894962,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/11,Other,,
766,894963,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/11,Other,,
767,894964,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/11,Other,,
768,894965,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/11,Other,,
769,894966,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/11,Other,,
770,894967,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/11,Other,,
771,894968,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/11,Other,,
772,894969,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/12,Other,,
773,894970,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/12,Other,,
774,894971,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/12,Other,,
775,894972,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/12,Other,,
776,894973,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/12,Other,,
777,894974,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/12,Other,,
778,894975,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/12,Other,,
779,894976,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/12,Other,,
780,894977,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/12,Other,,
781,894978,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/12,Other,,
782,894979,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/12,Other,,
783,894980,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/12,Other,,
784,894981,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/12,Other,,
785,894982,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/12,Other,,
786,894983,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/12,Other,,
787,894984,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/12,Other,,
788,894985,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/12,Other,,
789,894986,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/12,Other,,
790,894987,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/12,Other,,
791,895819,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/13,Other,,
792,895820,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/13,Other,,
793,895821,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/13,Other,,
794,895822,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/13,Other,,
795,895823,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/13,Other,,
796,895824,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/13,Other,,
797,895825,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/13,Other,,
798,895826,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/13,Other,,
799,895827,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/14,Other,,
800,895828,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/14,Other,,
801,895829,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/14,Other,,
802,895830,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/14,Other,,
803,895831,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/14,Other,,
804,895832,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/14,Other,,
805,895833,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/14,Other,,
806,895834,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/14,Other,,
807,895835,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/14,Other,,
808,895836,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/14,Other,,
809,895837,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/14,Other,,
810,895838,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/14,Other,,
811,895839,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/14,Other,,
812,895840,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/14,Other,,
813,895841,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/14,Other,,
814,895842,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/14,Other,,
815,895843,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/14,Other,,
816,895844,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/14,Other,,
817,895845,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/14,Other,,
818,895846,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/14,Other,,
819,895847,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/14,Other,,
820,895848,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/15,Other,,
821,895849,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/15,Other,,
822,895850,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/15,Other,,
823,895851,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/15,Other,,
824,895852,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/15,Other,,
825,896328,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/6,Other,,
826,896329,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/6,Other,,
827,896330,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/6,Other,,
828,896331,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/6,Other,,
829,896332,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/6,Other,,
830,896333,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/7,Other,,
831,896334,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/7,Other,,
832,896335,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/7,Other,,
833,896336,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/7,Other,,
834,896337,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/7,Other,,
835,896338,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/7,Other,,
836,896339,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/7,Other,,
837,896340,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/7,Other,,
838,896341,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/7,Other,,
839,896342,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/7,Other,,
840,896343,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/7,Other,,
841,896344,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/7,Other,,
842,896345,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/7,Other,,
843,896346,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/7,Other,,
844,896347,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/7,Other,,
845,896348,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/7,Other,,
846,896349,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/7,Other,,
847,896350,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/7,Other,,
848,896351,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/7,Other,,
849,896352,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/7,Other,,
850,896532,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/15,Other,,
851,896533,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/15,Other,,
852,896534,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/15,Other,,
853,896535,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/15,Other,,
854,896536,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/15,Other,,
855,896537,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/15,Other,,
856,896538,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/15,Other,,
857,896539,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/15,Other,,
858,896540,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/15,Other,,
859,896541,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/15,Other,,
860,896542,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/15,Other,,
861,896543,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/15,Other,,
862,896544,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/15,Other,,
863,896545,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/15,Other,,
864,897030,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/7,Other,,
865,897031,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/8,Other,,
866,897032,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/8,Other,,
867,897033,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/8,Other,,
868,897034,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/8,Other,,
869,897035,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/8,Other,,
870,897036,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/8,Other,,
871,897037,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/8,Other,,
872,897038,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/8,Other,,
873,897039,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/8,Other,,
874,897040,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/8,Other,,
875,897041,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/8,Other,,
876,897042,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/8,Other,,
877,897043,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/8,Other,,
878,897044,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/8,Other,,
879,897045,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/8,Other,,
880,897046,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/8,Other,,
881,897047,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/8,Other,,
882,897048,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/8,Other,,
883,897049,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/8,Other,,
884,897050,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/8,Other,,
885,897051,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/8,Other,,
886,897052,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/9,Other,,
887,897854,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/12,Other,,
888,897855,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/12,Other,,
889,897856,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/13,Other,,
890,897857,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/13,Other,,
891,897858,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/13,Other,,
892,897859,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/13,Other,,
893,897860,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/13,Other,,
894,897861,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/13,Other,,
895,897862,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/13,Other,,
896,897863,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/13,Other,,
897,897864,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/13,Other,,
898,897865,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/13,Other,,
899,897866,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/13,Other,,
900,897867,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/13,Other,,
901,897868,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/13,Other,,
902,897869,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/13,Other,,
903,897870,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/13,Other,,
904,897871,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/13,Other,,
905,897872,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/13,Other,,
906,897873,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/13,Other,,
907,897874,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/13,Other,,
908,897875,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/13,Other,,
909,897876,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/13,Other,,
910,897877,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/14,Other,,
911,897878,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/14,Other,,
912,897879,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/14,Other,,
913,897880,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/14,Other,,
914,897881,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/14,Other,,
915,897882,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/14,Other,,
916,897883,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/14,Other,,
917,897884,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/14,Other,,
918,897885,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/14,Other,,
919,897886,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/14,Other,,
920,897887,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/14,Other,,
921,897888,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/14,Other,,
922,897889,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/14,Other,,
923,897890,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/14,Other,,
924,897891,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/14,Other,,
925,897892,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/14,Other,,
926,897893,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/14,Other,,
927,898573,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/14,Other,,
928,898574,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/14,Other,,
929,898575,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/14,Other,,
930,898576,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/14,Other,,
931,898577,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/15,Other,,
932,898578,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/15,Other,,
933,898579,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/15,Other,,
934,899241,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/9,Other,,
935,899242,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/9,Other,,
936,899243,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/9,Other,,
937,899244,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/9,Other,,
938,899245,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/9,Other,,
939,899246,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/9,Other,,
940,899247,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/9,Other,,
941,899248,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/9,Other,,
942,899249,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/9,Other,,
943,899250,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/9,Other,,
944,899251,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/9,Other,,
945,899252,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/9,Other,,
946,899253,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/9,Other,,
947,899254,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/9,Other,,
948,899255,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/9,Other,,
949,899933,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/9,Other,,
950,899934,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/9,Other,,
951,899935,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/9,Other,,
952,899936,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/9,Other,,
953,899937,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/9,Other,,
954,899938,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/10,Other,,
955,899939,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/10,Other,,
956,899940,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/10,Other,,
957,899941,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/10,Other,,
958,899942,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/10,Other,,
959,899943,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/10,Other,,
960,899944,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/10,Other,,
961,899945,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/10,Other,,
962,899946,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/10,Other,,
963,899947,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/10,Other,,
964,899948,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/10,Other,,
965,899949,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/10,Other,,
966,899950,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/10,Other,,
967,899951,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/10,Other,,
968,899952,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/10,Other,,
969,899953,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/10,Other,,
970,899954,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/10,Other,,
971,899955,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/10,Other,,
972,899956,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/10,Other,,
973,899957,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/10,Other,,
974,899958,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/10,Other,,
975,899959,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/11,Other,,
976,899960,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/11,Other,,
977,899961,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/11,Other,,
978,899962,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/11,Other,,
979,899963,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/11,Other,,
980,899964,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/11,Other,,
981,899965,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/11,Other,,
982,900766,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/15,Other,,
983,900767,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/15,Other,,
984,900768,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/15,Other,,
985,900769,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/15,Other,,
986,900770,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/15,Other,,
987,900771,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/15,Other,,
988,900772,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/15,Other,,
989,900773,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/15,Other,,
990,900774,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/15,Other,,
991,900775,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/15,Other,,
992,900776,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/15,Other,,
993,900777,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/15,Other,,
994,900778,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/15,Other,,
995,900779,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/15,Other,,
996,900780,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/15,Other,,
997,900781,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/15,Other,,
998,900782,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/15,Other,,
999,900783,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/15,Other,,
1000,900784,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 368/16,Other,,
1001,900785,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 368/16,Other,,
1002,900786,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 368/16,Other,,
1003,900787,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 368/16,Other,,
1004,900788,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 368/16,Other,,
1005,900789,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 368/16,Other,,
1006,900790,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 368/16,Other,,
1007,900791,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 368/16,Other,,
1008,900792,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 368/16,Other,,
1009,900793,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 368/16,Other,,
1010,900794,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 368/16,Other,,
1011,900795,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 368/16,Other,,
1012,900796,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 368/16,Other,,
1013,901475,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 368/16,Other,,
1014,901476,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/16,Other,,
1015,901477,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/16,Other,,
1016,901478,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/16,Other,,
1017,901479,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/16,Other,,
1018,901480,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/16,Other,,
1019,901481,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/16,Other,,
1020,901482,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/16,Other,,
1021,902155,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/11,Other,,
1022,902156,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/11,Other,,
1023,902157,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/11,Other,,
1024,902158,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/11,Other,,
1025,902159,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/11,Other,,
1026,902838,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/11,Other,,
1027,902839,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/11,Other,,
1028,902840,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/11,Other,,
1029,902841,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/11,Other,,
1030,902842,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/11,Other,,
1031,902843,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/11,Other,,
1032,902844,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/11,Other,,
1033,902845,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/11,Other,,
1034,902846,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/11,Other,,
1035,902847,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/12,Other,,
1036,902848,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/12,Other,,
1037,902849,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/12,Other,,
1038,902850,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/12,Other,,
1039,902851,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/12,Other,,
1040,902852,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/12,Other,,
1041,902853,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/12,Other,,
1042,902854,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/12,Other,,
1043,902855,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/12,Other,,
1044,902856,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/12,Other,,
1045,902857,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/12,Other,,
1046,902858,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/12,Other,,
1047,902859,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/12,Other,,
1048,902860,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/12,Other,,
1049,902861,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/12,Other,,
1050,902862,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/12,Other,,
1051,902863,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/12,Other,,
1052,902864,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/12,Other,,
1053,902865,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/12,Other,,
1054,902866,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/12,Other,,
1055,902867,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/12,Other,,
1056,902868,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/13,Other,,
1057,902869,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/13,Other,,
1058,902870,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/13,Other,,
1059,902871,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/13,Other,,
1060,902872,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/13,Other,,
1061,902873,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/13,Other,,
1062,902874,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/13,Other,,
1063,902875,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/13,Other,,
1064,902876,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/13,Other,,
1065,902877,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/13,Other,,
1066,902878,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/13,Other,,
1067,902879,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/13,Other,,
1068,902880,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/13,Other,,
1069,904271,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/5,Other,,
1070,904272,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/5,Other,,
1071,904273,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/5,Other,,
1072,904274,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/5,Other,,
1073,904275,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/5,Other,,
1074,904276,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/5,Other,,
1075,904277,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/5,Other,,
1076,904278,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/5,Other,,
1077,904279,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/5,Other,,
1078,904280,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/5,Other,,
1079,904281,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/5,Other,,
1080,904282,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/5,Other,,
1081,904283,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/5,Other,,
1082,904284,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/5,Other,,
1083,904285,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/5,Other,,
1084,904286,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/5,Other,,
1085,904287,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 367/5,Other,,
1086,904288,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 367/5,Other,,
1087,904289,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 367/5,Other,,
1088,904290,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 367/5,Other,,
1089,904291,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 367/5,Other,,
1090,904974,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 367/6,Other,,
1091,904975,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 367/6,Other,,
1092,904976,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 367/6,Other,,
1093,904977,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 367/6,Other,,
1094,904978,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 367/6,Other,,
1095,904979,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 367/6,Other,,
1096,904980,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 367/6,Other,,
1097,904981,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 367/6,Other,,
1098,904982,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 367/6,Other,,
1099,904983,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 367/6,Other,,
1100,904984,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 367/6,Other,,
1101,904985,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 367/6,Other,,
1102,904986,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 367/6,Other,,
1103,904987,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 367/6,Other,,
1104,904988,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 367/6,Other,,
1105,904989,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 367/6,Other,,
1106,905827,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 368/10,Other,,
1107,905828,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 368/10,Other,,
1108,905829,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 368/10,Other,,
1109,905830,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 368/10,Other,,
1110,905831,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 368/10,Other,,
1111,905832,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 368/10,Other,,
1112,905833,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 368/10,Other,,
1113,925262,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020311,Other,,
1114,925263,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020311,Other,,
1115,925264,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020311,Other,,
1116,925265,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020311,Other,,
1117,925266,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020311,Other,,
1118,925267,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020311,Other,,
1119,925268,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020311,Other,,
1120,925269,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020311,Other,,
1121,925270,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020311,Other,,
1122,925271,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020311,Other,,
1123,925272,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020311",Other,,
1124,925273,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020311,Other,,
1125,925274,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020311,Other,,
1126,925275,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020311,Other,,
1127,925276,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020311,Other,,
1128,925277,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020311,Other,,
1129,925278,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020311,Other,,
1130,925279,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020311,Other,,
1131,925280,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020311,Other,,
1132,932293,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020311,Other,,
1133,932294,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020311,Other,,
1134,932295,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020311,Other,,
1135,932296,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020311,Other,,
1136,932297,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020311,Other,,
1137,932298,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020311,Other,,
1138,932299,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020311,Other,,
1139,932300,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020311,Other,,
1140,932301,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020311,Other,,
1141,932302,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020311,Other,,
1142,932303,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020311,Other,,
1143,932304,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020311,Other,,
1144,932305,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020311,Other,,
1145,932306,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020311,Other,,
1146,932307,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020311,Other,,
1147,932308,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020311",Other,,
1148,932309,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020311,Other,,
1149,932938,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020311,Other,,
1150,932939,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020311,Other,,
1151,934514,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020311,Other,,
1152,934515,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020311",Other,,
1153,934516,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020311,Other,,
1154,934517,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020311,Other,,
1155,934518,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020311,Other,,
1156,934519,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020311,Other,,
1157,934520,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020311,Other,,
1158,934521,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020311,Other,,
1159,934522,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020311,Other,,
1160,934523,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020311,Other,,
1161,934524,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020311,Other,,
1162,934525,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020311,Other,,
1163,934526,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020311,Other,,
1164,934527,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020311,Other,,
1165,935156,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020311,Other,,
1166,935157,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020311,Other,,
1167,935158,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020311,Other,,
1168,935159,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020311,Other,,
1169,935160,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020311,Other,,
1170,949944,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020311,Other,,
1171,950101,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020311,Other,,
1172,950102,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020311,Other,,
1173,950575,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020311,Other,,
1174,950576,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020311,Other,,
1175,950577,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020311,Other,,
1176,950578,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020311,Other,,
1177,950579,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020311,Other,,
1178,950580,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020311,Other,,
1179,950581,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020311,Other,,
1180,950582,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020311,Other,,
1181,950583,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020311,Other,,
1182,950584,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020311,Other,,
1183,950585,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020311,Other,,
1184,950586,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020311,Other,,
1185,950587,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020311,Other,,
1186,950588,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020311,Other,,
1187,950589,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020311,Other,,
1188,950590,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020311,Other,,
1189,962685,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020311,Other,,
1190,962686,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020311,Other,,
1191,962687,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020311,Other,,
1192,962688,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020311,Other,,
1193,962689,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020311,Other,,
1194,962690,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020311,Other,,
1195,962691,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020311,Other,,
1196,962692,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020311,Other,,
1197,962693,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020311,Other,,
1198,962694,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020311,Other,,
1199,962695,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020311,Other,,
1200,962696,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020311,Other,,
1201,962697,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020311,Other,,
1202,962698,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020311,Other,,
1203,962699,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020311,Other,,
1204,962700,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020311,Other,,
1205,962701,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020311,Other,,
1206,962702,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020311,Other,,
1207,962703,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020311,Other,,
1208,965785,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020311,Other,,
1209,965786,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020311,Other,,
1210,965787,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020311,Other,,
1211,965788,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020311,Other,,
1212,965789,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020311,Other,,
1213,965790,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020311,Other,,
1214,965791,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020311,Other,,
1215,965792,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020311,Other,,
1216,965793,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020311,Other,,
1217,965794,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020311,Other,,
1218,965795,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020311,Other,,
1219,965796,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020311,Other,,
1220,965797,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020311,Other,,
1221,965798,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020311,Other,,
1222,965799,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020311,Other,,
1223,965800,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020311,Other,,
1224,965801,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020311,Other,,
1225,965802,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020311,Other,,
1226,965803,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020311,Other,,
1227,978611,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020311",Other,,
1228,978612,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020311",Other,,
1229,978613,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1230,978614,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020311",Other,,
1231,978615,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020311",Other,,
1232,978616,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020311",Other,,
1233,978617,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020311,Other,,
1234,978618,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1235,978619,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020311",Other,,
1236,978620,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020311",Other,,
1237,978621,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020311",Other,,
1238,978622,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1239,978623,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020311",Other,,
1240,978624,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020311",Other,,
1241,978625,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1242,978626,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020311",Other,,
1243,978627,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020311",Other,,
1244,978628,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020311,Other,,
1245,978629,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1246,978630,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020311",Other,,
1247,978631,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1248,978632,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1249,978633,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1250,978634,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020311",Other,,
1251,978635,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1252,978636,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020311",Other,,
1253,980068,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1254,980069,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1255,980070,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020311,Other,,
1256,980071,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1257,980072,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020311",Other,,
1258,980073,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020311",Other,,
1259,980074,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020311",Other,,
1260,980075,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1261,980076,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020311",Other,,
1262,981588,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1263,981589,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1264,981590,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020311",Other,,
1265,982056,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020311",Other,,
1266,982057,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020311",Other,,
1267,982058,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020311",Other,,
1268,982059,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020311,Other,,
1269,982060,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020311",Other,,
1270,982061,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020311,Other,,
1271,982062,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020311",Other,,
1272,982063,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1273,982064,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020311",Other,,
1274,982065,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020311",Other,,
1275,982066,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1276,982067,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1277,982068,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020311",Other,,
1278,982069,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020311",Other,,
1279,982070,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1280,982071,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020311",Other,,
1281,982072,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020311",Other,,
1282,982073,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020311,Other,,
1283,982074,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1284,982075,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1285,982076,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1286,982077,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1287,982078,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1288,982079,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1289,982080,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1290,982081,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1291,982082,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020311",Other,,
1292,982083,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1293,982084,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1294,982085,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020311",Other,,
1295,982086,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1296,982087,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1297,982088,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020311",Other,,
1298,982089,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020311",Other,,
1299,982090,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020311",Other,,
1300,982091,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020311",Other,,
1301,982092,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020311",Other,,
1302,984081,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020311",Other,,
1303,984082,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020311,Other,,
1304,984083,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020311,Other,,
1305,984084,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020311",Other,,
1306,984085,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1307,984086,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1308,984087,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020311",Other,,
1309,984088,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020311",Other,,
1310,984089,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1311,984090,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1312,984091,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020311",Other,,
1313,984092,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020311",Other,,
1314,984093,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020311",Other,,
1315,984094,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020311",Other,,
1316,984095,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020311",Other,,
1317,984096,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1318,984097,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020311",Other,,
1319,984098,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020311",Other,,
1320,984099,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020311,Other,,
1321,984100,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020311",Other,,
1322,984101,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1323,984102,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1324,984103,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1325,984104,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020311",Other,,
1326,984105,1,3,,103188772,2160,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020311,Other,,
1327,984106,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1328,984107,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020311",Other,,
1329,984108,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1330,984109,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1331,984110,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020311",Other,,
1332,984111,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020311",Other,,
1333,984112,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1334,984113,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020311",Other,,
1335,984114,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1336,984115,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1337,984116,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020311",Other,,
1338,984584,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020311",Other,,
1339,984585,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1340,984586,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020311",Other,,
1341,984587,1,3,,103188772,2160,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020311",Other,,
1342,1036634,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/5,Other,,
1343,1036635,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/5,Other,,
1344,1036636,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/5,Other,,
1345,1036637,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/5,Other,,
1346,1036638,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/5,Other,,
1347,1036639,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/6,Other,,
1348,1036640,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/6,Other,,
1349,1036641,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/6,Other,,
1350,1036642,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/6,Other,,
1351,1036643,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/6,Other,,
1352,1036644,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/7,Other,,
1353,1036645,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/7,Other,,
1354,1036646,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/7,Other,,
1355,1036647,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/7,Other,,
1356,1036648,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/7,Other,,
1357,1036649,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/8,Other,,
1358,1036650,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/8,Other,,
1359,1036651,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/8,Other,,
1360,1036652,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/8,Other,,
1361,1036653,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/8,Other,,
1362,1036654,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/9,Other,,
1363,1036655,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/9,Other,,
1364,1036656,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/9,Other,,
1365,1036657,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/9,Other,,
1366,1036658,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/9,Other,,
1367,1036659,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/10,Other,,
1368,1036660,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/10,Other,,
1369,1036661,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/10,Other,,
1370,1036662,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/10,Other,,
1371,1036663,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/10,Other,,
1372,1036664,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/11,Other,,
1373,1036665,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/11,Other,,
1374,1036666,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/11,Other,,
1375,1038809,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/11,Other,,
1376,1038810,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/11,Other,,
1377,1039479,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/12,Other,,
1378,1039480,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/12,Other,,
1379,1039481,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/12,Other,,
1380,1039482,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/12,Other,,
1381,1039483,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/12,Other,,
1382,1039484,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/13,Other,,
1383,1039485,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/13,Other,,
1384,1039486,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/13,Other,,
1385,1039487,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/13,Other,,
1386,1039488,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/13,Other,,
1387,1039489,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/14,Other,,
1388,1039490,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/14,Other,,
1389,1039491,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/14,Other,,
1390,1039492,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/14,Other,,
1391,1039493,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/14,Other,,
1392,1039494,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/15,Other,,
1393,1039495,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/15,Other,,
1394,1039496,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/15,Other,,
1395,1039497,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/15,Other,,
1396,1039498,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/15,Other,,
1397,1039499,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 367/16,Other,,
1398,1039500,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 367/16,Other,,
1399,1039501,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 367/16,Other,,
1400,1039502,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 367/16,Other,,
1401,1039503,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 367/16,Other,,
1402,1039504,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/5,Other,,
1403,1039505,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/5,Other,,
1404,1039506,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/5,Other,,
1405,1039507,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/5,Other,,
1406,1039508,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/5,Other,,
1407,1039509,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/6,Other,,
1408,1039510,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/6,Other,,
1409,1039511,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/6,Other,,
1410,1039512,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/6,Other,,
1411,1039513,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/6,Other,,
1412,1039514,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/7,Other,,
1413,1039515,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/7,Other,,
1414,1039516,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/7,Other,,
1415,1039517,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/7,Other,,
1416,1039518,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/7,Other,,
1417,1039519,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/8,Other,,
1418,1039520,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/8,Other,,
1419,1039521,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/8,Other,,
1420,1039522,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/8,Other,,
1421,1039523,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/8,Other,,
1422,1042337,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/9,Other,,
1423,1042338,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/9,Other,,
1424,1042339,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/9,Other,,
1425,1042340,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/9,Other,,
1426,1042341,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/9,Other,,
1427,1042342,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/10,Other,,
1428,1042343,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/10,Other,,
1429,1042344,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/10,Other,,
1430,1042345,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/10,Other,,
1431,1042346,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/10,Other,,
1432,1042347,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/11,Other,,
1433,1042348,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/11,Other,,
1434,1042349,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/11,Other,,
1435,1042350,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/11,Other,,
1436,1042351,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/11,Other,,
1437,1042352,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/12,Other,,
1438,1042353,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/12,Other,,
1439,1042354,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/12,Other,,
1440,1042355,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/12,Other,,
1441,1042356,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/12,Other,,
1442,1042357,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/13,Other,,
1443,1042358,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/13,Other,,
1444,1042359,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/13,Other,,
1445,1042360,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/13,Other,,
1446,1042361,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/13,Other,,
1447,1042362,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/14,Other,,
1448,1042363,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/14,Other,,
1449,1042364,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/14,Other,,
1450,1042365,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/14,Other,,
1451,1042366,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/14,Other,,
1452,1042367,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/15,Other,,
1453,1042368,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/15,Other,,
1454,1042369,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/15,Other,,
1455,1042370,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/15,Other,,
1456,1042371,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/15,Other,,
1457,1042372,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 368/16,Other,,
1458,1042373,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 368/16,Other,,
1459,1042374,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 368/16,Other,,
1460,1043045,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 368/16,Other,,
1461,1043046,1,2,,103188772,2160,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 368/16,Other,,
1462,1063769,4,2,,103188772,2160,Active,400630.0,6532.0,0.00955,Ki,Displacement of [3H]Citalopram from serotonin transporter (unknown origin),Confirmatory,24365159.0,
1463,1079931,1,1,,103188772,2160,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1464,1079932,1,1,,103188772,2160,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1465,1079933,1,1,,103188772,2160,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1466,1079934,1,1,,103188772,2160,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1467,1079935,1,1,,103188772,2160,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1468,1079936,1,1,,103188772,2160,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1469,1079937,1,1,,103188772,2160,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1470,1079938,1,1,,103188772,2160,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1471,1079939,1,1,,103188772,2160,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1472,1079940,1,1,,103188772,2160,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1473,1079941,1,1,,103188772,2160,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1474,1079942,1,1,,103188772,2160,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1475,1079943,1,1,,103188772,2160,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1476,1079944,1,1,,103188772,2160,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1477,1079945,1,1,,103188772,2160,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1478,1079946,1,1,,103188772,2160,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1479,1079947,1,1,,103188772,2160,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1480,1079948,1,1,,103188772,2160,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1481,1079949,1,1,,103188772,2160,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1482,1097336,1,3,,103188772,2160,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
1483,1131083,1,1,,103188772,2160,Unspecified,,,,,Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins,Other,533882.0,
1484,1150604,1,1,,103188772,2160,Unspecified,,,,,Acute toxicity in ip dosed albino mouse assessed as mortality measured for 5 days,Other,950648.0,
1485,1150605,1,1,,103188772,2160,Unspecified,,,,,Antidepressant activity in ip dosed mouse assessed as prevention of reserpine-induced ptosis,Other,950648.0,
1486,1150606,1,1,,103188772,2160,Unspecified,,,,,Antidepressant activity in ip dosed rat assessed as prevention of tetrabenazine-induced ptosis,Other,950648.0,
1487,1159580,2,1,,268735243,2160,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1488,1159580,2,1,,273002711,2160,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1489,1159607,2,1,,312309770,2160,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1490,1189129,1,1,,103188772,2160,Active,,,35.11,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
1491,1189130,1,1,,103188772,2160,Active,,,42.18,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
1492,1189131,1,1,,103188772,2160,Active,,,36.05,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
1493,1189133,1,1,,103188772,2160,Active,,,3.03,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
1494,1189134,1,1,,103188772,2160,Unspecified,,,131.25,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
1495,1189135,1,1,,103188772,2160,Unspecified,,,10.81,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
1496,1189136,1,1,,103188772,2160,Active,,,1.16,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
1497,1189632,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,1800.0,Kd,Binding affinity to T292 residue of human recombinant TrkAIg2-NMR construct expressed in Escherichia coli by 1H-15N HSQC NMR spectroscopy,Confirmatory,25454499.0,
1498,1189633,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,2100.0,Kd,Binding affinity to V305 residue of human recombinant TrkAIg2-NMR construct expressed in Escherichia coli by 1H-15N HSQC NMR spectroscopy,Confirmatory,25454499.0,
1499,1189634,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,2100.0,Kd,Binding affinity to C345 residue of human recombinant TrkAIg2-NMR construct expressed in Escherichia coli by 1H-15N HSQC NMR spectroscopy,Confirmatory,25454499.0,
1500,1189635,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,2200.0,Kd,Binding affinity to F303 residue of human recombinant TrkAIg2-NMR construct expressed in Escherichia coli by 1H-15N HSQC NMR spectroscopy,Confirmatory,25454499.0,
1501,1189636,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,60.0,IC50,Displacement of [125I]NGF from full length human TrkA expressed in HEKN3S cells cells by gamma counting based radioligand competition assay,Confirmatory,25454499.0,
1502,1189637,1,2,,103188772,2160,Unspecified,94730402.0,4914.0,86.0,EC50,Antagonist activity at full length glycosylated human TrkA expressed in HEKN3S cells cells assessed as reduction in NGF-induced ERK 42/44 phosphorylation incubated for 5 mins by automated immunofluorescence assay,Confirmatory,25454499.0,
1503,1207148,1,1,,103188772,2160,Active,,,20.0,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
1504,1207179,1,1,,103188772,2160,Active,,,11.6,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
1505,1207207,1,1,,103188772,2160,Active,,,3.28,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
1506,1207238,1,2,,103188772,2160,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
1507,1207604,1,2,,103188772,2160,Active,116412.0,24239.0,23.2,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
1508,1207605,1,2,,103188772,2160,Active,116412.0,24239.0,3.75,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
1509,1209581,1,2,,103188772,2160,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1510,1209582,1,1,,103188772,2160,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1511,1209583,1,1,,103188772,2160,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1512,1209593,1,1,,103188772,2160,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1513,1215120,1,1,,103188772,2160,Active,,,1.01,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
1514,1215121,1,2,,103188772,2160,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
1515,1215122,1,1,,103188772,2160,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
1516,1215123,1,2,,103188772,2160,Unspecified,124028612.0,24186.0,134.0,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
1517,1215124,1,1,,103188772,2160,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
1518,1215125,1,1,,103188772,2160,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay,Other,21071520.0,
1519,1215126,1,2,,103188772,2160,Unspecified,,,,,Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
1520,1215128,1,1,,103188772,2160,Unspecified,,,,,"Ratio, ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM dosed as discrete compounds after 5 hrs by TRANSIL assay to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay",Other,21071520.0,
1521,1224859,2,1,,90340850,2160,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1522,1224863,1,1,,176484365,2160,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1523,1224863,1,1,,316919285,2160,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1524,1245889,1,1,,103188772,2160,Unspecified,,,40.0,GI50,Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,26372073.0,
1525,1257776,1,1,,103188772,2160,Active,547807.0,5979.0,1.0,IC50,"BindingDB_Patents: Kinase Assay. Approximately 5-20 microg of purified GST-RET proteins were incubated with 1 mM ATP in 20 microL kinase buffer (10 mM Tris-HCl, 5 mM MgCl2, pH 7.4), at 30 degrees  C. for 30 minutes. The kinase reactions were terminated by boiling the samples in SDS-PAGE sample buffer. Samples were resolved on 10% acrylamide gels by SDS-PAGE followed by Western blotting. Phosphorylation was detected using a pan-phosphotyrosine pY99 antibody (available from Santa Cruz Biotechnology) or RET phospho-specific antibody (pY905, available from Cell Signaling, Beverly, Mass., USA).",Confirmatory,,
1526,1259325,1,2,,336956242,2160,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1527,1259407,1,1,,363907121,2160,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1528,1259416,1,2,,340079492,2160,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1529,1259416,1,2,,375178094,2160,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1530,1259421,1,1,,340079492,2160,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1531,1259421,1,1,,375178094,2160,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1532,1259423,1,2,,354790421,2160,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1533,1259423,1,2,,354811149,2160,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1534,1259423,1,2,,354937436,2160,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1535,1259423,1,2,,354941040,2160,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1536,1259423,1,2,,354965080,2160,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
